The company assembles data about long term survivors of cancer, thus hoping to crack the code on what keeps people alive.
Cure51 has raised €15M across 1 funding round from 5 investors, most recently a Seed round in Mar 2024. Based in Paris, France; active in Healthtech. Data as of 7 Aug 2026.
Timing: overdue vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2024-03-20 | Seed | €15M |
| Hitachi Ventures,Life Extension Ventures,Olivier Pomel,Sofinnova Partners,Xavier Niel |
| View deal → |
